Munditia Technologies GmbH, based in Giessen, specializes in the development, synthesis, and marketing of antimicrobial substances and formulations. The company operates as a small entity under the German Commercial Code (HGB) and employs no staff beyond its two managing directors. Financing is primarily provided by shareholder capital, with the company reporting a balance sheet over-indebtedness for the 2024 fiscal year. Business activities are focused on research and development in the field of antimicrobials.
Entwicklung, Synthese und Vermarktung von antimikrobiell wirksamen Substanzen und Formulierungen.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Gießen Local Court, HRB 9911 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Andreas Fritsch | Geschäftsführer(in) | Rott |
| Klaus Schepers | Geschäftsführer(in) | Braunfels |
Source: German Commercial Register (Handelsregister) Gießen Local Court, HRB 9911 (as of 30 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | Rohergebnis€28.4K2 | -€229,857 | €595,576 | — |
| 2024 | Rohergebnis€41.3K2 | -€282,170 | €584,179 | — |
| 2023 | Rohergebnis-€59.9K2 | -€369,811 | €556,159 | — |
| 2022 | Rohergebnis€9K2 | -€385,295 | €540,841 | 2 |
| 2021 | Rohergebnis€86.5K2 | -€114,095 | €467,131 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Gießen Local Court, HRB 9911 (as of 30 October 2026)
Protomedical GmbH
Zell am Harmersbach · Herstellung von pharmazeutischen Grundstoffen
PAION AG
Aachen · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
BioNTech SE
Mainz · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €161,738 | 89.4% |
| Depreciation | €19,191 | 10.6% |
